First International Conference on RASopathies in Asia: Advances in RASopathies and Neurofibromatosis
Identification of New Therapeutic Targets
27th – 29th November 2017, Crowne Plaza, Kochi, Kerala, South India

PROGRAMME

DAY 1: CLINICAL ASPECTS OF NF1, NF2 AND SWANNOMATOSIS

0815 - 0855  Registration
Chairs:  Professor Eric Legius & Professor Bronwyn Kerr

0855 - 0900  Welcome and Introduction, Professor Meena Upadhyaya

0900 - 0940  RASopathies overview
Professor Kate Rauen, California, USA

0940 - 1010  Neurofibromatosis type 1
Dr Susan Huson, Manchester, UK

1010 - 1025  RASopathies: Indian Experience
Ratna Puri, Delhi, India

1025 - 1040  RASopathies: Indian experience
Professor Ashok Pillai, Kochi, India

1040 - 1105  NF1 mutational spectrum and quest for genotype phenotype
Professor Ludwine Messiaen, Birmingham, USA

1105 - 1110  Mutation Databases
Dr Rick Van Minkelen, Rotterdam, Netherlands

1110 - 1140  Coffee
Chairs:  Professor Bruce Korf & Dr Jaishri Blakeley

1140 - 1210  Neurofibromatosis type 2
Professor Gareth Evans, Manchester, UK

1210 - 1215  Role of NF2 Clinical nurse specialists
Anup Raji, Manchester, UK

1215 - 1245  Drug Development for NF2
Dr Vijya Ramesh, Boston, USA

1245 - 1315  Clinical trials and management for NF2
Dr Jaishri Blakeley, Baltimore, USA

1315 - 1415  Lunch
Chairs: Professor Nancy Ratner, Professor Brigitte Widemann

1415 - 1445  Swannomatosis
Professor Scott Plotkin, Boston, USA

1445 - 1515  Pathology of tumours
Anat Stemmer-Rachamimov, Boston, USA

1515 - 1630  A typical neurofibromas and MPNSTs
Professor Eric Legius, Leaven, Belgium

1630 - 1700  NF1 tumours/OPG
Dr Mike Fisher, Philadelphia, USA

1700 - 1710  NF1 and Breast Cancer
Ian Frayling, Cardiff, UK

1710 - 1720  The NF1 somatic mutational landscape in sporadic human cancers
Professor Meena Upadhyaya, Cardiff, Uk

1720 - 1730  Dysregulation of pigment epithelium derived factor in café au lait macules melanocytes promotes proliferation, migration and invasiveness
Girish Patel, Cardiff, UK

1730 - 1930  Poster Session

1930  Gala Dinner accompanied by renowned Classical Music and Bollywood Dancing

DAY 2: TRANSLATIONAL RESEARCH/CLINICAL APPLICATION, DIAGNOSIS AND MANAGEMENT OF RASOPATHIES FOCUSING ON CASE STUDIES

0700 - 0800  Registration

Chairs: Dr Mike Fisher & Dr Vijya Ramesh

0800 - 0845  What causes malignant peripheral nerve sheath tumours to develop?
Professor Luis Parada, New York, USA

0845 - 0925  Preclinical testing
Professor Nancy Ratner, Cincinnatti, USA

0925 - 0935  MEK1/2 inhibitors CIP-137401
Dr Uday Khire, Boston, USA

0935 - 1005  Development of effective therapies for benign and malignant peripheral nerve sheath tumours
Professor Brigitte Widemann, Bethesda, USA

1005 - 1035  Coffee

Chairs: Suma Shankar & Girisha KM

1035 - 1105  Learning disabilities in RASopathy
Professor Ype Elgersma, Rotterdam, Netherlands

1105 - 1135  Neurofibromatoses: Past, present and future...
Professor Pierre Wolkenstein, Paris, France
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 1135 - 1210 | Genomic Guided Therapeutics for NF1  
Professor Bruce Korf, Birmingham, USA |
| 1210 - 1310 | Lunch, Poster session                                                   |
| 1310 - 1455 | Clinical and molecular diagnosis and management of RASopathies- Interactive Session with Panel Discussion  
Facilitators: Professor Kate Rauen, Dr Susan Huson, Professor Bronwyn Kerr, Shubha Phadke |

Shubha Phadke, Lucknow, India  
Abeer Alsaegh-, Muscat, Oman  
Sheela Nampoothiri, Kochi, India  
Joanne Ngeow, Singapore  
Isabel Cordeiro, Lisbon, Portugal  
Shay Ben Shachar, Israel  
Ahmet Caglayan, Turkey  
Niby J Elackatt, Organisation for Rare Diseases, India  
Yemima Berman, Sydney, Australia |
| 1455 - 1530 | Questions & Discussion                                                  |
| 1530 | Coffee                                                                  |

Dinner at Cherai Beach (Coaches will be arranged)  
Kathakali Dance and other entertainments |

**DAY 3: CLINICAL ASPECTS OF RASOPATHIES, CLINICAL TRIALS, PANEL DISCUSSION ON MEK1 INHIBITOR (Selumetinib)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 - 0800</td>
<td>Registration</td>
</tr>
</tbody>
</table>

**Chairs: Professor Kate Rauen & Professor Miikka Vikkula**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 0800 - 0830 | Noonan Syndrome  
Professor Bronwyn Kerr, Manchester, UK |
| 0830 - 0900 | Legius syndrome  
Professor Eric Legius, Leaven, Belgium |
| 0900 - 0930 | Costello  
Professor Bronwyn Kerr, Manchester, UK |
| 0930 - 1000 | CFC  
Professor Kate Rauen, California, USA |
| 1000 - 1030 | Capillary Malformation- Arteriovenous Malformation (CM-AVM)  
Professor Miikka Vikkula, Brussels, Belgium |
| 1030 - 1100 | Coffee                                                                  |
1100 - 1230  Panel Discussion: Selumetinib (MEK1/2 inhibitor) in treating patients with NF1
Facilitator: Professor Gareth Evans

Professor Brigitte Widemann, Professor Eric Legius, Professor Nancy Ratner
Professor Kate Rauen, Professor Bruce Korf, Professor Pierre Walkenstein,
Professor Scott Plotkin, Professor Luis Parada, Dr Mike Fisher, Dr Jaisree Blakeley

Chairs: Professor Luis Parada and Dr Joshi George

1230 - 1245  Spinal Neurofibromas Surgery
Dr Anant Tambe, Manchester, UK

1245 - 1315  Clinical trials for RASopathies
Dr Suma Shankar, California, USA

1315 - 1400  Future Directions for RASopathies
Professor Bruce Korf, Alabama, USA

1400  MEETING ENDS